ReviewFrontiers in immunology2026
Metabolic reprogramming in ulcerative colitis: integrating dietary drivers, pathogenesis, and therapeutic advances.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a complex disorder characterized by gene-environment interactions that compromise the integrity of the mucosa and submucosa. The current evidence indicates a significant correlation between the increasing incidence of UC and the consumption of a Western diet. Dietary patterns alter the nutritional composition, thus inducing metabolic shifts in the intestinal microenvironment that disrupt gut homeostasis and contribute to the development of UC. Mechanistically, metabolic abnormalities in epithelial cells, macrophages, neutrophils, and other cell types compromise the integrity of the intestinal epithelial barrier and modulate immune-inflammatory responses, promoting the onset and progression of UC. Furthermore, the dysregulation of microbial metabolites disrupts gut microbiota homeostasis, contributing to disease progression. Here, we summarize the association between the dietary pattern and UC risk; we further elaborate on the metabolic alterations in colonic epithelial cells, immune cells, and the gut microbiota during UC; and we discuss how these changes influence disease progression. Finally, we discuss potential therapeutic strategies targeting metabolic reprogramming for UC management. By integrating insights from macroepidemiology and micromolecular mechanisms, we delineate the association between metabolic reprogramming and UC and provide a valuable reference for future research into key mechanisms and novel treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.